AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 billion ... revenue growth rate for aesthetics through 2029. Price Action: ABBV shares are trading higher by 7.87% to $189. ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...

In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ... data emerges that might require relatively quick action. Also, a strong balance sheet helps biopharma ...

Rinvoq forecasts also see a slight boost of ... expected in 2025 to guide long-term growth projections. Price Action: ABBV stock is up 3.5% at $176.32 at last check Monday.

Rinvoq total sales were more than $1.8 billion ... we reinstated our original Alle consumer loyalty program earlier this month. This action has been met with a rapid and favorable response ...

Key Insights: Action Taken: Analysts frequently update ... with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta).

To watch more expert insights and analysis on the latest market action, check out more Morning ... raised its long-term outlook for Skyrizi and Rinvoq by $4 billion. Investing.com - Shares in ...

While sales of Skyrizi rose 57.9% on an operational basis, Rinvoq sales were up 47.1% ... stocks – and investors who get in on the action early enough. Our urgent report, Atomic Opportunity ...

The FDA's action date on the drug was originally in April but has been pushed back twice. European regulators have also already approved Olumiant and Rinvoq for the inflammatory skin disorder.

There's already stiff competition in the oral psoriasis category, however, from drugs with different mechanisms of action ... like Skyrizi and JAK inhibitor Rinvoq (upadacitinib).